Apremilast in Treatment-Refractory Recurrent Aphthous Stomatitis by Kolios, Antonios G A et al.








Apremilast in Treatment-Refractory Recurrent Aphthous Stomatitis
Kolios, Antonios G A ; Yawalkar, Nikhil ; Feusi, Arlene ; Kündig, Thomas ; Boyman, Onur ; Nilsson,
Jakob
DOI: https://doi.org/10.1056/nejmc1901987





Kolios, Antonios G A; Yawalkar, Nikhil; Feusi, Arlene; Kündig, Thomas; Boyman, Onur; Nilsson, Jakob
(2019). Apremilast in Treatment-Refractory Recurrent Aphthous Stomatitis. New England Journal of
Medicine, 381(20):1975-1977.
DOI: https://doi.org/10.1056/nejmc1901987
C o r r e s p o n d e n c e
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 381;20 nejm.org November 14, 2019
Apremilast in Treatment-Refractory Recurrent Aphthous 
Stomatitis
To the Editor: Recurrent aphthous stomatitis 
is a chronic, painful ulcerative disease of the 
oral mucosa that may be resistant to treatment. 
Its clinical heterogeneity has complicated classifi-
cation of the disorder, but variants in cytokine 
genes, including tumor necrosis factor α (TNF-α), 
have been reported and suggest a role for cyto-
kines in the pathogenesis of the disorder.1 De-
pending on disease severity, treatment may in-
clude topical and systemic glucocorticoids, 
colchicine, dapsone, and TNF-α inhibitors, and 
there have been case reports of responses to 
apremilast.2-4 Apremilast is an oral phosphodies-
terase-4 inhibitor that inhibits production of pro-
inflammatory cytokines, including TNF-α, and 
is approved for the treatment of psoriasis and 
psoriatic arthritis. A phase 2 trial5 and a phase 3 
trial by Hatemi et al. (the results of which are 
reported in this issue of the Journal) have shown 
efficacy of apremilast in treating the oral ulcers 
in patients with Behçet’s disease.
We report a retrospective series of five patients 
with recurrent aphthous stomatitis who were 
treated with apremilast (standard induction over 
a period of 5 days, followed by a dose of 30 mg 
twice daily) for 2 to 24 months (mean, 11.4 
months) (Table 1). Details regarding treatment 
administration are provided in the Supplemen-
tary Appendix, available with the full text of this 
letter at NEJM.org. The lesions in these patients 
had been refractory to conventional treatment 
with topical glucocorticoids and colchicine. Alter-
native diagnoses, including Behçet’s disease, in-
f lammatory bowel disease, and infection, were 
evaluated and were ruled out on the basis of 
history, bacterial and viral swabs, colonoscopy 
with biopsies, the absence of HLA-B51 in three 
patients, and negative pathergy testing in two 
patients. Biopsies of active lesions revealed ulcer-
ation with neutrophil-rich infiltration in four 
patients. Written informed consent was provided 
by all the patients for off-label treatment with 
apremilast, and the study was approved by the 
regional ethics review board. All the authors 
vouch for the accuracy of the data and for the 
reporting of adverse events that occurred in the 
patients who were treated with apremilast.
Patients were evaluated by means of the Phy-
sician Global Assessment (PGA) at baseline and 
follow-up; the assessment uses a five-point scale, 
with scores ranging from 0 (clear) to 1 (almost 
clear), 2 (mild), 3 (moderate), and 4 (severe). 
Follow-up visits for safety and efficacy evalua-
tions occurred within 2 to 6 weeks after the start 
of therapy and at various times thereafter.
Over a period of 2 to 6 weeks of apremilast 
therapy at a dose of 30 mg twice daily, a com-
plete response (PGA score of 0) was observed in 
four of the five patients, and the fifth patient 
had a PGA score of 1 (almost clear) (Table 1 and 
Fig. S1 in the Supplementary Appendix). After 
1 year of treatment, Patient 4 could reduce the 
apremilast dose to 30 mg once daily with persis-
tent control, whereas the other three patients 
had control maintained with the use of 30 mg of 
apremilast twice daily. At 24 months of contin-
ued treatment, a PGA score of 1 was maintained 
in four of five patients. Treatment was associated 
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*  The Physician Global Assessment (PGA) uses a five-point scale, with scores ranging from 0 (clear) to 1 (almost clear), 2 (mild), 3 (moderate), and 4 (severe). Clearance was defined as 
a score of 0 or 1 and was observed in all five patients at some point in weeks 2 through 6. NA denotes not applicable (because the patient discontinued treatment at 2 months).
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with intermittent gastrointestinal side effects in 
all patients (Table S1 in the Supplementary Ap-
pendix). Persistent headache and weight loss, 
which led to treatment discontinuation, devel-
oped in one patient.
In conclusion, in an uncontrolled series in-
volving five patients at one institution, apremilast 
therapy reduced disease activity in treatment-
refractory recurrent aphthous stomatitis. The 
small number of patients and retrospective na-
ture of our study limit its generalizability. Trials 
of apremilast for treatment-resistant recurrent 
aphthous stomatitis may be appropriate.
Antonios G.A. Kolios, M.D.
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Selinexor for Refractory Multiple Myeloma
To the Editor: In the article by Chari et al. (Aug. 
22 issue)1 on oral selinexor for multiple myeloma, 
we noticed that one of the most common grade 3 
or 4 adverse events was hyponatremia (serum 
sodium level, <130 mmol per liter) (in 22% of the 
patients). This appears to be a class effect of 
selinexor, because other studies of this agent 
had similar incidences of hyponatremia, ranging 
from 7 to 26%.2-5 The incidence of hyponatre-
mia was higher in studies involving patients 
with multiple myeloma than in studies involv-
ing patients with solid tumors. No workup was 
performed or no cause was found in many of 
the studies. In patients with multiple myeloma, 
hyponatremia is not a common clinical finding. 
A direct effect on water transport through nu-
clear-export modulation by selinexor cannot be 
ruled out.
Involvement of nephrology consultation in 
ongoing trials might be useful to investigate 
the mechanism of this adverse event. Measure-
ment of serum and urine osmolality along with 
urine electrolyte levels would help in assess-
ment of the cause and pathophysiology of the 
hyponatremia. This will then allow for preven-
tive strategies in further trials and clinical 
practice.
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